

President) 600 Atlantic Avenue, Boston, Massachusetts 02210-2204:

1. *Pentucket Bank Holdings, MHC, and Pentucket Bancorp, Inc.*, both in Haverhill, Massachusetts; to become bank holding companies by acquiring 100 percent of the voting shares of Pentucket Bank, Haverhill, Massachusetts.

B. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Eastern Michigan Financial Corporation, Croswell, Michigan*; to merge with Ruth Bank Corporation, and thereby indirectly acquire voting shares of Ruth State Bank, both in Ruth, Michigan.

C. Federal Reserve Bank of Minneapolis (Jacquelyn K. Brunmeier, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291:

1. *First Bancshares Corporation, Gladstone, Michigan*; to acquire 100 percent of the voting shares of Northern Michigan Bank & Trust, Escanaba, Michigan.

D. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *CSBO Holdings, Inc., Employee Stock Ownership Plan, Ridgway, Colorado*; to become a bank holding company by acquiring 51 percent of the voting shares of CSBO Holdings, Inc., Ridgway, Colorado, and thereby indirectly acquire voting shares of Citizens State Bank of Ouray, Ouray, Colorado.

Board of Governors of the Federal Reserve System, December 15, 2015.

**Michael J. Lewandowski,**

*Associate Secretary of the Board.*

[FR Doc. 2015-31889 Filed 12-18-15; 8:45 am]

**BILLING CODE 6210-01-P**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at

the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than January 4, 2016.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *Janet McCauslin, Chillicothe, Missouri; John Littrell, Brookfield, Missouri, as a group acting in concert, and Allen D. Powell Bank Share Trust, and Allen Powell, as trustee, both of Linneus, Missouri*; to acquire voting shares of Capital Bancshares, Inc., and thereby indirectly acquire voting shares of Bank of Brookfield-Purdin, N.A., both in Brookfield, Missouri.

Board of Governors of the Federal Reserve System, December 15, 2015.

**Michael J. Lewandowski,**

*Associate Secretary of the Board.*

[FR Doc. 2015-31888 Filed 12-18-15; 8:45 am]

**BILLING CODE 6210-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC-2015-0014]

#### Final Revised Vaccine Information Materials for Pneumococcal Conjugate Vaccine (PCV13)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** Under the National Childhood Vaccine Injury Act (NCVIA)(42 U.S.C. 300aa-26), the CDC must develop vaccine information materials that all health care providers are required to give to patients/parents prior to administration of specific vaccines. On May 20, 2015, CDC published a notice in the **Federal Register** (80 FR 29009) seeking public comments on proposed updated vaccine information materials for pneumococcal conjugate vaccine (PCV13). Following review of comments submitted and consultation as required under the law, CDC has finalized the materials. Copies of the final vaccine information materials for pneumococcal conjugate vaccine (PCV13) are available to download from <http://www.cdc.gov/vaccines/hcp/vis/index.html> or <http://www.regulations.gov> (see Docket Number CDC-2015-0014).

**DATES:** Beginning no later than March 1, 2016, each health care provider who administers pneumococcal conjugate vaccine (PCV13) to any child or adult in the United States shall provide copies of the relevant vaccine information materials contained in this notice, in conformance with the November 5, 2015 CDC Instructions for the Use of Vaccine Information Statements prior to providing such vaccinations.

#### FOR FURTHER INFORMATION CONTACT:

Suzanne Johnson-DeLeon ([msj1@cdc.gov](mailto:msj1@cdc.gov)), National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Mailstop A-19, 1600 Clifton Road NE., Atlanta, Georgia 30329.

**SUPPLEMENTARY INFORMATION:** The National Childhood Vaccine Injury Act of 1986 (Pub. L. 99-660), as amended by section 708 of Public Law 103-183, added section 2126 to the Public Health Service Act. Section 2126, codified at 42 U.S.C. 300aa-26, requires the Secretary of Health and Human Services to develop and disseminate vaccine information materials for distribution by all health care providers in the United States to any patient (or to the parent or legal representative in the case of a child) receiving vaccines covered under the National Vaccine Injury Compensation Program (VICP).

Development and revision of the vaccine information materials, also known as Vaccine Information Statements (VIS), have been delegated by the Secretary to the Centers for Disease Control and Prevention (CDC). Section 2126 requires that the materials be developed, or revised, after notice to the public, with a 60-day comment period, and in consultation with the Advisory Commission on Childhood Vaccines, appropriate health care provider and parent organizations, and the Food and Drug Administration. The law also requires that the information contained in the materials be based on available data and information, be presented in understandable terms, and include:

- (1) A concise description of the benefits of the vaccine,
- (2) A concise description of the risks associated with the vaccine,
- (3) A statement of the availability of the National Vaccine Injury Compensation Program, and
- (4) Such other relevant information as may be determined by the Secretary.

The vaccines initially covered under the National Vaccine Injury Compensation Program were diphtheria, tetanus, pertussis, measles, mumps, rubella, and poliomyelitis vaccines. Since April 15, 1992, any health care